We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · November 23, 2022

Identification of Patients With Ovarian Cancer With Highest Benefit From First-Line Bevacizumab Based on Their Tumor-Intrinsic Chemosensitivity

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
J. Clin. Oncol 2022 Oct 17;[EPub Ahead of Print], B You, C Purdy, LJ Copeland, EM Swisher, MA Bookman, G Fleming, R Coleman, LM Randall, KS Tewari, BJ Monk, RS Mannel, JL Walker, F Cappuccini, D Cohn, M Muzaffar, D Mutch, A Wahner-Hendrickson, L Martin, O Colomban, RA Burger

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading